SLC1A5 co-expression with TALDO1 associates with endocrine therapy failure in estrogen receptor-positive breast cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1573-7217
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
SLC1A5 co-expression with TALDO1 associates with endocrine therapy failure in estrogen receptor-positive breast cancer ; volume:189 ; number:2 ; day:19 ; month:7 ; year:2021 ; pages:317-331 ; date:9.2021
Breast cancer research and treatment ; 189, Heft 2 (19.7.2021), 317-331, 9.2021
- Urheber
-
Alfarsi, Lutfi H.
El Ansari, Rokaya
Craze, Madeleine L.
Mohammed, Omar J.
Masisi, Brendah K.
Ellis, Ian O.
Rakha, Emad A.
Green, Andrew R.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s10549-021-06298-1
- URN
-
urn:nbn:de:101:1-2021103122464464671782
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:22 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Alfarsi, Lutfi H.
- El Ansari, Rokaya
- Craze, Madeleine L.
- Mohammed, Omar J.
- Masisi, Brendah K.
- Ellis, Ian O.
- Rakha, Emad A.
- Green, Andrew R.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Co-expression of YAP and TAZ associates with chromosomal instability in human cholangiocarcinoma
Factors associated with initiation and continuation of endocrine therapy in women with hormone receptor-positive breast cancer
PPFIA1 expression associates with poor response to endocrine treatment in luminal breast cancer
Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer
Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer
CDK4/6 Inhibitors—Overcoming Endocrine Resistance Is the Standard in Patients with Hormone Receptor-Positive Breast Cancer
microRNA Regulation in Estrogen Receptor-Positive Breast Cancer and Endocrine Therapy
Phase III study of long-term prognosis of estrogen receptor-positive early breast cancer treated with neoadjuvant endocrine therapy with/without adjuvant chemotherapy
E2112: randomized phase iii trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer
Clinical efficacy of combined goserelin and anastrozole in neoadjuvant endocrine therapy for premenopausal women with hormone receptor-positive breast cancer
piRNA associates with immune diseases
Mec1p associates with functionally compromised telomeres
Co-expression of YAP and TAZ associates with chromosomal instability in human cholangiocarcinoma
Factors associated with initiation and continuation of endocrine therapy in women with hormone receptor-positive breast cancer
PPFIA1 expression associates with poor response to endocrine treatment in luminal breast cancer
Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer
Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer
CDK4/6 Inhibitors—Overcoming Endocrine Resistance Is the Standard in Patients with Hormone Receptor-Positive Breast Cancer
microRNA Regulation in Estrogen Receptor-Positive Breast Cancer and Endocrine Therapy
Phase III study of long-term prognosis of estrogen receptor-positive early breast cancer treated with neoadjuvant endocrine therapy with/without adjuvant chemotherapy
E2112: randomized phase iii trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer
Clinical efficacy of combined goserelin and anastrozole in neoadjuvant endocrine therapy for premenopausal women with hormone receptor-positive breast cancer
piRNA associates with immune diseases
Mec1p associates with functionally compromised telomeres
Co-expression of YAP and TAZ associates with chromosomal instability in human cholangiocarcinoma
Factors associated with initiation and continuation of endocrine therapy in women with hormone receptor-positive breast cancer
PPFIA1 expression associates with poor response to endocrine treatment in luminal breast cancer
Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer
Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer
CDK4/6 Inhibitors—Overcoming Endocrine Resistance Is the Standard in Patients with Hormone Receptor-Positive Breast Cancer
microRNA Regulation in Estrogen Receptor-Positive Breast Cancer and Endocrine Therapy
Phase III study of long-term prognosis of estrogen receptor-positive early breast cancer treated with neoadjuvant endocrine therapy with/without adjuvant chemotherapy
E2112: randomized phase iii trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer
Clinical efficacy of combined goserelin and anastrozole in neoadjuvant endocrine therapy for premenopausal women with hormone receptor-positive breast cancer
piRNA associates with immune diseases